Pyrimidothienoindazoles

1. A compound of formula

wherein

R 1 is selected from the group consisting of hydrogen, methyl, ethyl, and halo;

R 2 is selected from the group consisting of hydrogen, methyl, ethyl, and halo;

R 3 is selected from the group consisting of hydrogen, alkyl, halo, hydroxy, alkoxy, trifluoromethoxy, benzyloxy, halogenated benzyloxy, alkylated benzyloxy, pyridoxy, alkylated pyridoxy, halogenated pyridoxy, pyridylmethoxy, halogenated pyridylmethoxy, and N-morpholinyl, or

R 2 and R 3 , together with the carbon atoms to which they are attached, form an pyrazole ring, wherein said pyrazole ring can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of alkyl, benzyl, halogenated benzyl, pyridylmethoxy, and halogenated pyridylmethoxy;

R 4 is selected from the group consisting of hydrogen, alkyl, cyano, and halo;

R 5 is selected from the group consisting of hydrogen, alkyl, and halo;

R 6 is selected from the group consisting of hydrogen, and alkyl;

R 7 is selected from the group consisting of hydrogen, and alkyl, or

R 7 is a heterocycle selected from the group consisting of pyrrolidinyl, morpholinyl, piperidinyl, and piperazinyl, or

R 7 is alkyl selected from the group consisting of methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl, wherein said alkyl is substituted with 1, 2 or 3 independently selected substituents R 7−1 ,

wherein R 7−1 is selected from the group consisting of halo, hydroxy, alkoxy, alkylsulfonyloxy, and amino, or

R 7−1 is alkylamino, wherein said alkylamino can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of hydroxy, alkoxy, amino, alkylamino, alkylsulfonyl, pyrrolidinyl, morpholinyl, piperidinyl, and piperazinyl, or

R 7−1 is alkenylamino, wherein said alkenylamino can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of oxo, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyl, N-pyrrolidinyl, N-morpholinyl, N-piperidinyl, and N-piperazinyl, or

R 7−1 is a heterocycle selected from the group consisting of pyrrolidinyl, imidazolidinyl, imidazolyl, pyrazolyl, morpholinyl, piperidinyl, piperazinyl, and thiomorpholinyl, wherein said heterocycle can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of alkyl, halo, hydroxy, alkoxy, amino, alkylamino, hydroxyalkyl, alkoxyalkyl, carboxyl, alkoxycarbonyl, N-pyrrolidinyl, N-piperidinyl, N-piperazinyl, pyrazinyl, benzyl, and pyridylmethyl, or

R 7 is alkenyl selected from the group consisting of allyl, prop-1-enyl, 2-methyl-prop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, wherein said alkenyl is substituted with 1, 2 or 3 independently selected substituents R 7−2 ,

wherein R 7−2 is oxo, or

wherein R 7−2 is alkylamino, wherein said alkylamino can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of oxo, hydroxy, alkoxy, amino, and alkylamino;

or a salt thereof.

2. The compound of claim 1 , wherein

R 1 is hydrogen;

R 2 is hydrogen;

R 3 is selected from the group consisting of hydrogen, halo, hydroxy, methoxy, ethoxy, n-propyloxy, i-propyloxy, trifluoromethoxy, benzyloxy, halogenated benzyloxy, pyridoxy, methylated pyridoxy, ethylated pyridoxy, halogenated pyridoxy, pyridylmethoxy, halogenated pyridylmethoxy, and N-morpholinyl, or

R 2 and R 3 , together with the carbon atoms to which they are attached, form an pyrazole ring, wherein said pyrazole ring can optionally be substituted with 0 or 1 substituents benzyl;

R 4 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, cyano, and halo;

R 5 is hydrogen;

R 6 is hydrogen;

R 7 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and amino, or

R 7 is alkyl selected from the group consisting of methyl, ethyl, and n-propyl, wherein said alkyl is substituted with 1 or 2 independently selected substituents R 7−1 ,

wherein R 7−1 is selected from the group consisting of halo, hydroxy, methoxy, ethoxy, n-propyloxy, i-propyloxy, methylsulfonyloxy, amino, or

R 7−1 is alkylamino, wherein said alkylamino can optionally be substituted with 0, 1 or 2 substituents independently selected from the group consisting of hydroxy, methoxy, ethoxy, n-propyloxy, i-propyloxy, amino, methylamino, ethylamino, dimethylamino, diethylamino, methylethylamino, methylsulfonyl, N-pyrrolidinyl, and N-morpholinyl, or

R 7−1 is a heterocycle selected from the group consisting of N-pyrrolidinyl, N-imidazolyl, N-morpholinyl, N-piperidinyl, N-piperazinyl, and N-thiomorpholinyl, wherein said heterocycle can optionally be substituted with 0 or 1 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, i-propyl, halo, hydroxy, methoxy, ethoxy, n-propyloxy, i-propyloxy, amino, methylamino, ethylamino, dimethylamino, diethylamino, methylethylamino, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, i-propyloxycarbonyl, n-butyloxycarbonyl, i-butyloxycarbonyl, t-butyloxycarbonyl, N-pyrrolidinyl, N-piperidinyl, N-piperazinyl, pyrazinyl, benzyl, and pyridylmethyl;

or a salt thereof.

3. The compound of claim 1 , wherein R 1 , R 2 , and R 5 are hydrogen, R 3 is 2-pyridylmethoxy and R 4 is chloro.

4. The compound of claim 1 , wherein R 1 , R 2 , and R 5 are hydrogen, R 3 is fluoro and R 4 is chloro.

5. The compound of claim 1 , wherein R 1 , R 2 , R 4 , and R 5 are hydrogen, and R 3 is 3-fluorobenzyloxy.

6. A process for preparing the compounds of the formula (I), wherein a compound of formula (II)

wherein R 1 to R 7 have the meaning indicated in claim 1 ,

is oxidized with a oxidising agent or oxidant.

7. A pharmaceutical composition comprising a compound according to claim 1 .

8. The pharmaceutical composition according to claim 7 in combination with at least one pharmaceutically acceptable excipient.

9. A process for preparing a pharmaceutical composition comprising a compound according to claim 1 in combination with at least one pharmaceutically acceptable excipient, comprising the steps of combining at least one compound of claim 1 with at least one pharmaceutically acceptable excipient, mixing the combination and bringing the combination into a suitable administration form.

10. The packaged pharmaceutical composition comprising a container comprising the pharmaceutical composition of claim 7 and instructions for using the pharmaceutical composition.